Maffezzini M, Simonato A, Lodolo C, Raber M, Carmignani G
Clinica Urologica University of Trieste, Italy.
Tumori. 1995 May-Jun;81(3):191-3. doi: 10.1177/030089169508100307.
Intravesical instillations commonly follow resection, when all visible lesions have been removed, making impossible any direct assessment of efficacy. The study was conceived to evaluate the ablative effect on the tumor and the efficacy in reducing the risk of recurrence of short schedule intravesical chemotherapy administered before endoscopic resection.
Four weekly intravesical instillations of mitomycin C followed by transurethral resection (TUR) were administered to 31 patients with recurrent small volume superficial bladder cancer.
At TUR no evidence of disease was found in 22 patients (70.9%) and residual disease in the remaining 9 (29.1%). At a median follow-up of 15 months (range, 3-33) 16 of 31 patients (51.6%) had recurrence of disease. The treatment was well tolerated.
Short-schedule intravesical chemotherapy can completely ablate small volume recurrent superficial bladder cancer in a relevant number of patients but is probably not sufficient to obtain long-term prophylaxis.
膀胱内灌注通常在切除术后进行，此时所有可见病变均已切除，因而无法直接评估疗效。本研究旨在评估内镜切除术前短疗程膀胱内化疗对肿瘤的消融作用以及降低复发风险的疗效。
对31例复发性小体积浅表性膀胱癌患者，每周进行4次丝裂霉素C膀胱内灌注，随后行经尿道切除术（TUR）。
TUR时，22例患者（70.9%）未发现疾病证据，其余9例（29.1%）有残留疾病。中位随访15个月（范围3 - 33个月）时，31例患者中有16例（51.6%）疾病复发。该治疗耐受性良好。
短疗程膀胱内化疗可使相当数量的患者完全消融复发性小体积浅表性膀胱癌，但可能不足以实现长期预防。
